Improving vision in adults with amblyopia using optical correction
Spectacle Correction for the Treatment of Amblyopia
This study is testing whether wearing special glasses can help improve vision in adults with amblyopia, a condition where one eye doesn't see as well as the other.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | Centre for Eye and Vision Research Academic / other |
| Locations | 2 sites (Waterloo, Ontario and 1 other locations) |
| Trial ID | NCT05394987 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of optical correction on visual functions in adults with amblyopia, a condition characterized by reduced visual acuity due to abnormal visual experiences in early life. Participants aged 18-39 with specific types of amblyopia will receive spectacles to assess improvements in their best corrected visual acuity and other visual functions. The study aims to explore the potential for neuroplasticity in adults and how refractive correction can enhance vision. Functional measures related to vision, binocular vision, and eye movements will be utilized to evaluate the efficacy of the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-39 with anisometropic or mixed mechanism amblyopia and specific visual acuity criteria.
Not a fit: Patients with other ocular anomalies causing reduced visual acuity or those currently undergoing amblyopia treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved visual acuity and overall visual functions in adults suffering from amblyopia.
How similar studies have performed: Previous studies have suggested that optical correction can improve visual functions in amblyopia, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-39 (inclusive) years of age * Anisometropic amblyopia (difference of ≥0.50D spherical equivalent or ≥1.50D astigmatism between eyes) or mixed mechanism amblyopia (strabismus and anisometropia) * Best corrected visual acuity (BCVA) in the amblyopic eye of 0.3 logMAR to 1.0 logMAR (inclusive) * BCVA in the non-amblyopic eye of 0.1 logMAR or better, and an interocular VA difference of 2 logMAR lines or more * Difference of 1.00D or more between current refractive correction and study prescription * Good general health Exclusion Criteria: * Other pathological ocular anomalies known to cause reduced visual acuity * Presbyopia (based on amplitude of accommodation) * Inability to tolerate prescribed refractive correction in spectacles (e.g., due to aniseikonia) * Contraindication to cycloplegic eye drops * Currently under amblyopia treatment/therapy * Inability to comprehend test instructions and/or provide consent * Eccentric fixation * \>-6.00DS of myopia in either eye with spectacles * Bilateral amblyopia * Presence of amblyopia that is not due to strabismus and/or anisometropia * Presence of (current or previous) psychiatric, visual, or neurological disorders
Where this trial is running
Waterloo, Ontario and 1 other locations
- University of Waterloo — Waterloo, Ontario, Canada (Recruiting)
- Centre for Eye and Vision Research Limited — Hong Kong, Guangdong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Benjamin Thompson, PhD — Centre for Eye and Vision Research Limited
- Study coordinator: Benjamin Thompson, PhD
- Email: ben.thompson@cevr.hk
- Phone: +852-3169-9631
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.